Eastern Cooperative Oncology Group

描述（由申请人提供）：约翰霍普金斯自1955年以来一直是ECOG的成员。我们的主要目标是将在约翰霍普金斯试行的创新临床研究方案和实验室相关科学引入本集团，以进一步发展。 与此同时，我们的教师担任研究主席和实验室联合主席，疾病和模式为导向的委员会主席的领导角色。 具体目标是：1）继续在疾病导向委员会中提供科学领导：乳腺、胸、头颈、泌尿生殖系统、脑肿瘤工作组、淋巴瘤、白血病; 2）扩大我们对疾病和模式委员会的参与：胃肠道、骨髓瘤、药理学和药物开发; 3）将相关转化研究、细胞生物学和分子生物学纳入疾病所有阶段的临床方案; 4）扩大我们的应计项目，并保持卓越的数据质量。 我们希望通过约翰霍普金斯大学悉尼金梅尔综合癌症中心的使命实现这些目标：为癌症研究提供多学科方法，从而改善预防、诊断和治疗手段。 该中心在转化研究方面取得了卓越成就，获得了六项SPORE赠款（淋巴瘤，G-I癌症，前列腺，乳腺，肺，头颈部）。 此外，我们还进行新药的早期临床试验（自1982年以来一直与NCI签订I期合同），并持有II期重点早期治疗药物开发合同。这些赠款允许开发新的II期和III期试验概念，我们的教师将这些概念带到ECOG，并进行适当的实验室科学相关研究。 我们的应计费用和委员会的参与预计将继续增长，因为扩大临床项目和教师与新的癌症中心设施和研究大楼自2000年底以来占用成为可能。

DESCRIPTION (provided by applicant): Johns Hopkins has been a member of ECOG since 1955. Our primary goal is to bring innovative clinical research protocols and laboratory correlative science piloted at Johns Hopkins to the Group for further development. In conjunction with this, our faculty serves in leadership roles as study chairs and laboratory co-chairs, disease and modality-oriented committee chairs. The specific aims are: 1) to continue to provide scientific leadership in the disease-oriented committees: Breast, Thoracic, Head and Neck, Genitourinary, Brain Tumor Working Group, Lymphoma, Leukemia; 2) to expand our involvement to the disease and modality committees: Gastro-intestinal, Myeloma, Pharmacology and Drug Development; 3) to bring translational research correlates, cell biology and molecular biology into clinical protocols for all stages of disease; 4) to expand our accrual and maintain excellence in data quality. We expect to accomplish these goals through the mission of the Sydney Kimmel Comprehensive Cancer Center at Johns Hopkins: to provide a multidisciplinary approach to the study of cancer that will result in improved means for prevention, diagnosis and treatment. The Center has achieved excellence in translational research with the awarding of six SPORE grants (lymphoma, G-I cancer, prostate, breast, lung, head and neck). In addition, we perform early clinical trials of new drugs (NCI phase I contract since 1982) and hold a contract for Early Therapeutics Development with Phase II Emphasis. These grants allow the development of novel phase II and phase Ill trial concepts which our faculty bring to ECOG with appropriate laboratory science correlative studies. Our accrual and committee involvement is expected to continue to grow because of expanding clinical programs and faculty made possible with a new Cancer Center facility and research buildings occupied since late 2000.